Arabic Arabic English English French French German German
dark

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Compugen Ltd. announced that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination of COM902, the Company’s potential best-in-class, high-affinity anti-TIGIT antibody and COM701, Compugen’s first-in-class anti-PVRIG antibody in patients with advanced malignancies who have exhausted all available standard therapies. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Next Post

NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy

Related Posts
Total
0
Share